GB201416352D0 - Spirocyclic derivatives - Google Patents
Spirocyclic derivativesInfo
- Publication number
- GB201416352D0 GB201416352D0 GBGB1416352.1A GB201416352A GB201416352D0 GB 201416352 D0 GB201416352 D0 GB 201416352D0 GB 201416352 A GB201416352 A GB 201416352A GB 201416352 D0 GB201416352 D0 GB 201416352D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- spirocyclic derivatives
- spirocyclic
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416352.1A GB201416352D0 (en) | 2014-09-16 | 2014-09-16 | Spirocyclic derivatives |
| CN201580059377.7A CN107108625A (zh) | 2014-09-16 | 2015-09-14 | 螺环衍生物 |
| PCT/IB2015/057030 WO2016042452A1 (en) | 2014-09-16 | 2015-09-14 | Spirocyclic derivatives |
| AU2015316471A AU2015316471A1 (en) | 2014-09-16 | 2015-09-14 | Spirocyclic derivatives |
| BR112017005242A BR112017005242A2 (pt) | 2014-09-16 | 2015-09-14 | composto, composição farmacêutica, e, composto para uso. |
| JP2017534017A JP2017527631A (ja) | 2014-09-16 | 2015-09-14 | スピロ環状誘導体 |
| CA2997868A CA2997868A1 (en) | 2014-09-16 | 2015-09-14 | Spirocyclic derivatives |
| US15/511,443 US9908897B2 (en) | 2014-09-16 | 2015-09-14 | Spirocyclic derivatives |
| EP15774986.2A EP3201195A1 (en) | 2014-09-16 | 2015-09-14 | Spirocyclic derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416352.1A GB201416352D0 (en) | 2014-09-16 | 2014-09-16 | Spirocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201416352D0 true GB201416352D0 (en) | 2014-10-29 |
Family
ID=51869695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1416352.1A Ceased GB201416352D0 (en) | 2014-09-16 | 2014-09-16 | Spirocyclic derivatives |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9908897B2 (OSRAM) |
| EP (1) | EP3201195A1 (OSRAM) |
| JP (1) | JP2017527631A (OSRAM) |
| CN (1) | CN107108625A (OSRAM) |
| AU (1) | AU2015316471A1 (OSRAM) |
| BR (1) | BR112017005242A2 (OSRAM) |
| CA (1) | CA2997868A1 (OSRAM) |
| GB (1) | GB201416352D0 (OSRAM) |
| WO (1) | WO2016042452A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831818A (zh) * | 2017-02-07 | 2017-06-13 | 上海合全药业股份有限公司 | 一种2‑叔丁基‑7‑甲基‑5‑氧杂‑2,8‑二氮杂螺烷‑[3,5]壬烷‑2,7‑二羧酸的制备方法 |
| EP3604305B1 (en) | 2017-03-24 | 2024-08-28 | Wakunaga Pharmaceutical Co., Ltd. | Novel pyridone carboxylic acid derivative or salt thereof |
| CN108164542A (zh) * | 2018-01-05 | 2018-06-15 | 天津药明康德新药开发有限公司 | 外消旋-9-氨基-6-氧杂-2-氮杂螺[4.5]癸烷-2-羧酸叔丁基酯的合成方法 |
| WO2020048827A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds |
| CN112679405B (zh) * | 2019-10-17 | 2023-12-15 | 南京富润凯德生物医药有限公司 | 一种(s)-7-氧杂-2-氮杂螺[4.5]癸烷衍生物的制备方法 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| CN113200997B (zh) * | 2021-05-07 | 2023-10-03 | 上海合全医药有限公司 | 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法 |
| US20250002503A1 (en) * | 2021-09-20 | 2025-01-02 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
| CN115894489A (zh) * | 2021-09-22 | 2023-04-04 | 中国药科大学 | 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU150489A (sh) * | 1989-08-10 | 1992-12-21 | W.L. Gore & Co. Gmbh. | Uređaj za ispitivanje odevnih predmeta na nepromočivost |
| FR2734265B1 (fr) | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US6835371B1 (en) | 1997-09-12 | 2004-12-28 | David R. Elmaleh | Diagnostic and therapeutic piperazine and piperidine compounds and process |
| TR200201684T2 (tr) | 1999-12-30 | 2002-10-21 | H. Lundbeck A/S | Fenilpiperazinil türevleri |
| DK1315750T3 (da) | 2000-08-30 | 2007-06-11 | Hoffmann La Roche | Cykliske peptider med melanocortin-4-receptoragonistaktivitet |
| EP1519939B9 (en) * | 2002-07-05 | 2011-04-06 | Targacept, Inc. | N-aryl diazaspirocyclic compounds and methods of preparation and use thereof |
| EP1683797A1 (en) * | 2003-11-13 | 2006-07-26 | Ono Pharmaceutical Co., Ltd. | Heterocyclic spiro compound |
| CN101022801A (zh) * | 2004-08-20 | 2007-08-22 | 塔加西普特公司 | N-芳基二氮杂螺环化合物在成瘾治疗中的用途 |
| AU2006306542B2 (en) * | 2005-10-21 | 2012-04-19 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| GB0707934D0 (en) * | 2007-04-24 | 2007-05-30 | Glaxo Group Ltd | Chemical compounds |
| EP2606049A4 (en) * | 2010-08-17 | 2014-01-08 | Albany Molecular Res Inc | 2,5-METHANO- AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USES THEREOF FOR BLOCKING NOREPINEPHRINE, DOPAMINE, AND SEROTONIN REUPTAKE |
| US20130116241A1 (en) * | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| CN105612152A (zh) | 2013-08-26 | 2016-05-25 | 普渡制药公司 | 氮杂螺[4.5]癸烷衍生物及其用途 |
| JP6574438B2 (ja) * | 2014-03-17 | 2019-09-11 | リマインド エヌヴイRemynd Nv | 2,7−ジアザスピロ[3.5]ノナン化合物 |
-
2014
- 2014-09-16 GB GBGB1416352.1A patent/GB201416352D0/en not_active Ceased
-
2015
- 2015-09-14 US US15/511,443 patent/US9908897B2/en active Active
- 2015-09-14 JP JP2017534017A patent/JP2017527631A/ja active Pending
- 2015-09-14 CN CN201580059377.7A patent/CN107108625A/zh active Pending
- 2015-09-14 WO PCT/IB2015/057030 patent/WO2016042452A1/en not_active Ceased
- 2015-09-14 BR BR112017005242A patent/BR112017005242A2/pt not_active IP Right Cessation
- 2015-09-14 CA CA2997868A patent/CA2997868A1/en not_active Abandoned
- 2015-09-14 EP EP15774986.2A patent/EP3201195A1/en not_active Withdrawn
- 2015-09-14 AU AU2015316471A patent/AU2015316471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017527631A (ja) | 2017-09-21 |
| US20170253615A1 (en) | 2017-09-07 |
| EP3201195A1 (en) | 2017-08-09 |
| CN107108625A (zh) | 2017-08-29 |
| WO2016042452A1 (en) | 2016-03-24 |
| CA2997868A1 (en) | 2016-03-24 |
| AU2015316471A1 (en) | 2017-04-20 |
| BR112017005242A2 (pt) | 2017-12-12 |
| US9908897B2 (en) | 2018-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201701322WA (en) | Special effects techniques | |
| ZA201704602B (en) | Dihydroindolizinone derivative | |
| GB201416346D0 (en) | Spirocyclic derivatives | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| GB201416352D0 (en) | Spirocyclic derivatives | |
| IL254662A0 (en) | Spirocyclic compounds | |
| PL3164393T3 (pl) | Pochodne flawaglin | |
| HUE050450T2 (hu) | Fluoralkil-fluorén-származékok | |
| IL248773A0 (en) | History of naphthyridinedione | |
| IL248629A0 (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| PT3097076T (pt) | Novos derivados cyp-eicosanoides | |
| HUE041392T2 (hu) | Etinil származékok | |
| IL248772A0 (en) | A consequence of cyclohexyl pyridine | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| SG11201704985VA (en) | Fumagillol derivatives | |
| GB2523854B (en) | Circuitry | |
| PL3012253T3 (pl) | Pochodne tetrahydrofuranu | |
| HK1242319A1 (zh) | 螺环衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |